Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
$7.36
$7.67
$7.13
$21.08
$485.98M1.44667,653 shs3.38 million shs
JSE
Jadestone Energy
C$0.50
+6.4%
C$0.50
C$0.42
C$1.60
C$230.52MN/A65,927 shs7,530 shs
Pharming Group stock logo
PHAR
Pharming Group
$9.60
-2.3%
$10.86
$9.27
$16.71
$644.26M0.162,623 shs4,437 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
0.00%0.00%0.00%0.00%0.00%
JSE
Jadestone Energy
0.00%0.00%0.00%0.00%0.00%
Pharming Group stock logo
PHAR
Pharming Group
-2.93%-0.16%-11.36%-22.01%-11.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
0.6656 of 5 stars
2.00.00.00.00.60.02.5
JSE
Jadestone Energy
N/AN/AN/AN/AN/AN/AN/AN/A
Pharming Group stock logo
PHAR
Pharming Group
2.613 of 5 stars
3.55.00.00.02.60.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
2.00
Hold$9.0022.28% Upside
JSE
Jadestone Energy
N/AN/AN/AN/A
Pharming Group stock logo
PHAR
Pharming Group
3.00
Buy$37.00285.42% Upside

Current Analyst Ratings

Latest CJ, SAVP, RRE, JSE, and PHAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2024
Pharming Group stock logo
PHAR
Pharming Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
$2.22B0.22$3.74 per share1.97$17.13 per share0.43
JSE
Jadestone Energy
C$279.18M0.83C$0.09 per share5.55C$0.49 per share1.03
Pharming Group stock logo
PHAR
Pharming Group
$245.32M2.63$0.10 per share98.49$3.26 per share2.94

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
-$130.01M$0.819.09N/AN/A-15.12%-3.35%-2.68%N/A
JSE
Jadestone Energy
N/AC$0.059.80N/AN/AN/AN/AN/A
Pharming Group stock logo
PHAR
Pharming Group
-$10.55M-$0.14N/AN/AN/A-4.13%-4.53%-2.14%5/8/2024 (Confirmed)

Latest CJ, SAVP, RRE, JSE, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Pharming Group stock logo
PHAR
Pharming Group
$0.0050N/A-$0.0050N/AN/AN/A
3/14/2024Q4 2023
Pharming Group stock logo
PHAR
Pharming Group
$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
N/AN/AN/AN/AN/A
JSE
Jadestone Energy
N/AN/AN/AN/AN/A
Pharming Group stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
0.02
2.15
1.92
JSE
Jadestone Energy
57.41
1.17
0.71
Pharming Group stock logo
PHAR
Pharming Group
0.62
4.06
3.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
N/A
JSE
Jadestone Energy
N/A
Pharming Group stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
1.50%
JSE
Jadestone Energy
N/A
Pharming Group stock logo
PHAR
Pharming Group
2.07%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
C&J Energy Services Inc stock logo
CJ
C&J Energy Services
6,39966.03 millionN/AOptionable
JSE
Jadestone Energy
N/A461.04 millionN/ANot Optionable
Pharming Group stock logo
PHAR
Pharming Group
33267.11 million65.72 millionNot Optionable

CJ, SAVP, RRE, JSE, and PHAR Headlines

SourceHeadline
Pharming to be honored as Industry Innovator at National  Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsPharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
finance.yahoo.com - April 24 at 2:17 AM
Pharming Group to report first quarter 2024 financial results on May 8Pharming Group to report first quarter 2024 financial results on May 8
finance.yahoo.com - April 24 at 2:17 AM
Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00
marketbeat.com - April 22 at 1:31 PM
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
zacks.com - April 22 at 6:31 AM
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreasePharming Group (NASDAQ:PHAR) Sees Large Volume Increase
americanbankingnews.com - April 21 at 4:44 AM
Pharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35Pharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35
americanbankingnews.com - April 20 at 4:40 AM
Pharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025Pharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
finanznachrichten.de - April 19 at 4:05 PM
Pharming Group (NASDAQ:PHAR) Sees Strong Trading VolumePharming Group (NASDAQ:PHAR) Sees Strong Trading Volume
marketbeat.com - April 19 at 1:37 PM
Pharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029Pharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029
finanznachrichten.de - April 18 at 6:18 PM
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
finance.yahoo.com - April 18 at 8:17 AM
Pharming Group (NASDAQ:PHAR) Stock Price Down 6.8%Pharming Group (NASDAQ:PHAR) Stock Price Down 6.8%
marketbeat.com - April 15 at 1:55 PM
Pharming Group (NASDAQ:PHAR)  Shares Down 5% Pharming Group (NASDAQ:PHAR) Shares Down 5%
marketbeat.com - April 9 at 3:19 PM
Enrollment completed for trial of drug to treat children with rare primary immunodeficiencyEnrollment completed for trial of drug to treat children with rare primary immunodeficiency
outsourcing-pharma.com - April 8 at 8:50 AM
Pharming announces completion of enrollment in pediatric clinical trial of leniolisibPharming announces completion of enrollment in pediatric clinical trial of leniolisib
finance.yahoo.com - April 8 at 1:34 AM
Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96
marketbeat.com - April 4 at 6:21 PM
Pharming Group announces the filing of its 2023 Annual Report and Form 20-FPharming Group announces the filing of its 2023 Annual Report and Form 20-F
finance.yahoo.com - April 4 at 1:14 AM
Uber to pay $178 million in Australia taxi class action settlementUber to pay $178 million in Australia taxi class action settlement
msn.com - March 18 at 3:45 AM
Pharming reports Q4 resultsPharming reports Q4 results
msn.com - March 15 at 7:46 PM
Pharming Group N.V. 2023 Q4 - Results - Earnings Call PresentationPharming Group N.V. 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 14 at 9:06 AM
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14
finanznachrichten.de - February 29 at 6:26 AM
Pharming Group N.V. (PHGN.F)Pharming Group N.V. (PHGN.F)
finance.yahoo.com - February 20 at 3:10 PM
Pharming Group N.V.: Pharming Group to participate in February investor conferencesPharming Group N.V.: Pharming Group to participate in February investor conferences
finanznachrichten.de - February 8 at 3:55 AM
Pharming Group to participate in February investor conferencesPharming Group to participate in February investor conferences
finance.yahoo.com - February 8 at 3:55 AM
Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data ReadoutAstria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
seekingalpha.com - February 5 at 12:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

C&J Energy Services logo

C&J Energy Services

NYSE:CJ
C&J Energy Services, Inc. provides well construction, well completion, well support, and other complementary oilfield services and technologies to oil and gas exploration and production companies throughout the continental United States. It operates through Completion Services and Well Support Services segments. The Completion Services segment provides hydraulic fracturing; cased-hole solutions comprising cased-hole wireline, pumpdown, wireline logging, perforating, pressure pumping, well site make-up and pressure testing, and other complementary services; and well construction and intervention services, which include cementing, coiled tubing, rig services, fluids management, and other completion and well support services. This segment also engages in the engineering and production of various parts and components, such as perforating guns and addressable switches, which are used in the completion process. The Well Support Services segment offers rig services, such as providing workover and well servicing rigs that are primarily used for the routine repair and maintenance of oil and gas wells, re-drilling operations, and plugging and abandonment operations; fluids management services, including storage, transportation, and disposal services for fluids used in the drilling, completion, and workover of oil and gas wells; and other special well site services, such as fishing, contract labor, and tool rental services for the completion and workover of oil and gas wells. The company was founded in 1997 and is headquartered in Houston, Texas.

Jadestone Energy

CVE:JSE
Jadestone Energy Inc., together with its subsidiaries, engages in the production, development, and exploration and appraisal activities in Australia, Indonesia, Vietnam, and the Philippines. Its two producing assets include the Stag Oilfield located in the Carnarvon Basin, offshore Western Australia with a total proved and probable reserves of 17.1 million barrels of oil; and the Ogan Komering production sharing contract located onshore South Sumatra, Indonesia. The company's portfolio also comprises approximately 44,000 square kilometers of exploration and pre-development acreage across the Philippines, Vietnam, and Indonesia. Jadestone Energy Inc. is headquartered in Singapore.
Pharming Group logo

Pharming Group

NASDAQ:PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.